

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

December 2014

Vol. 42, No. 12

CONTENTS

MINIREVIEW

- ☐ Drug Disposition and Drug-Drug Interaction Data in 2013 FDA New Drug Applications: A Systematic Review. *Jingjing Yu, Tasha K. Ritchie, Aditi Mulgaonkar, and Isabelle Ragueneau-Majlessi*. **1991**

SHORT COMMUNICATION

- ☐ Systematic Identification and Characterization of Carboxylesterases in Cynomolgus Macaques. *Yasuhiro Uno, Shotaro Uehara, Masakiyo Hosokawa, and Teruko Imai*. **2002**

SYMPOSIUM REPORT

- Role of (Drug) Transporters in Imaging in Health and Disease. *Bruno Stieger, Jashvant D. Unadkat, Bhagwat Prasad, Oliver Langer, and Hariprasad Gali*. **2007**

ARTICLES

- Wuzhi Tablet (*Schisandra Sphenanthera* Extract) Protects against Acetaminophen-Induced Hepatotoxicity by Inhibition of CYP-Mediated Bioactivation and Regulation of NRF2-ARE and p53/p21 Pathways. *Xiaomei Fan, Yiming Jiang, Ying Wang, Huasen Tan, Hang Zeng, Yongtao Wang, Pan Chen, Aijuan Qu, Frank J. Gonzalez, Min Huang, and Huichang Bi*. **1982**
- ☐ Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans. *Adam S. Darwich, Umair Aslam, Darren M. Ashcroft, and Amin Rostami-Hodjegan*. **2016**
- Disposition and Metabolic Profiling of [¹⁴C]Cerlapirdine Using Accelerator Mass Spectrometry. *Susanna Tse, Louis Leung, Sangeeta Raje, Mark Seymour, Yoko Shishikura, and R. Scott Obach*. **2023**
- ☐ Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. *Tadashi Namisaki, Elke Schaeffeler,*

- Hiroshi Fukui, Hitoshi Yoshiji, Yoshiyuki Nakajima, Peter Fritz, Matthias Schwab, and Anne T. Nies*. . . **2033**

- ☐ Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3. *Rym Chioukh, Marie-Sophie Noel-Hudson, Sandy Ribes, Natalie Fournier, Laurent Becquemont, and Celine Verstyft*. **2041**

- Aldehyde Oxidase Activity in Fresh Human Skin. *Nenad Manevski, Kamal Kumar Balavenkatraman, Barbara Bertschi, Piet Swart, Markus Walles, Gian Camenisch, Hilmar Schiller, Olivier Kretz, Barbara Ling, Reto Wettstein, Dirk J. Schaefer, Francois Pognan, Armin Wolf, and Karine Litherland*. **2049**

- ☐ In Vitro Metabolism and Drug-Drug Interaction Potential of UTL-5g, a Novel Chemo- and Radioprotective Agent. *Jianmei Wu, Jiajiu Shaw, Sarah Dubaisi, Frederick Valeriote, and Jing Li*. **2058**

- ☐ Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. *Jukka Mäenpää, Marjo Volotinen-Maja, Hannu Kautiainen, Mikko Neuvonen, Mikko Niemi, Pertti J. Neuvonen, and Janne T. Backman*. **2068**

- ☐ Effect of Prostaglandin E₂ on Multidrug Resistance Transporters In Human Placental Cells. *Clifford W. Mason, Gene T. Lee, Yafeng Dong, Helen Zhou, Lily He, and Carl P. Weiner*. **2077**

- ☐ Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Two Piperazine-Containing Compounds. *Amanda K. Bolles, Rina Fujiwara, Erran D. Briggs, Amin A. Nomeir, and Laura Lowe Furge*. **2087**

- ☐ Enhanced Methamphetamine Metabolism in Rhesus Macaque as Compared with Human: An Analysis Using a Novel Method of Liquid Chromatography with Tandem Mass Spectrometry, Kinetic

Continued on next page

Study, and Substrate Docking. *Ravinder Earla, Santosh Kumar, Lei Wang, Steven Bosinger, Junhao Li, Ankit Shah, Mohitkumar Gangwani, Anantha Nookala, Xun Liu, Lu Cao, Austin Jackson, Peter S. Silverstein, Howard S. Fox, Weihua Li, and Anil Kumar* **2097**

An Orphan Esterase ABHD10 Modulates Probenecid Acyl Glucuronidation in Human Liver. *Yusuke Ito, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima* **2109**

LETTERS TO THE EDITOR

Breast Cancer Resistance Protein Substrate and Inhibition Evaluation: Why, When, and How? *Joseph A. Ware, Bradley L. Urquhart, Yuichi Sugiyama, and Maciej J. Zamek-Gliszczyński* . . . **1979**

Response to “Breast Cancer Resistance Protein Substrate and Inhibition Evaluation: Why, When, and How?” *Agnès Poirier, Mohammed Ullah, and Christoph Funk* **1981**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Expression of OCT3 protein in hepatocellular carcinoma and corresponding liver tissue. Immunohistochemical staining of drug uptake transporter OCT3 was performed on formalin-fixed and paraffin-embedded tissue samples from nontumor tissue (F) and HCC tissue of trabecular (G) or pseudoglandular (H) growth pattern. The median staining scores (blue horizontal lines) for OCT3 were significantly lower in HCC tissue than in nontumor tissue (E, $P < 0.001$). Scale bars, 20 μm . See the article by Namisaki et al. ([dx.doi.org/10.1124/dmd.114.059832](https://doi.org/10.1124/dmd.114.059832)).